Seattle Genetics (SGEN +4.4%) surges after RBC's Jason Kantor boosts his 2011 and 2012 sales...

|About: Seattle Genetics, Inc. (SGEN)|By:, SA News Editor

Seattle Genetics (SGEN +4.4%) surges after RBC's Jason Kantor boosts his 2011 and 2012 sales forecasts for the company's recently-approved Adcetris drug for treating lymphoma. Kantor claims an RBC survey of 100 hematologists suggests "rapid early adoption" of Adcetris.